Pfizer will list its COVID-19 treatment Paxlovid at a price of $1,390 per five-day course when it soon hits the commercial market, the drugmaker confirmed to Axios.

Why it matters: Paxlovid’s new listed price, first reported by the Wall Street Journal, will be more than twice the $529 paid by the federal government, which until now has maintained the entire U.S. supply of the key antiviral medication.

  • thepianistfroggollum@lemmynsfw.com
    link
    fedilink
    English
    arrow-up
    2
    arrow-down
    5
    ·
    1 year ago

    Only 2.6% of the sample were given paxlovid, and they didn’t control for vaccination status.

    Also, it only covered 1 month nearly 2 years ago in a single country, and the virus has mutated several times since then.

    • SoleInvictus@lemmy.world
      link
      fedilink
      arrow-up
      2
      ·
      1 year ago

      The best part about having a background in statistics is watching people who don’t understand statistics try to explain why the math that doesn’t support their point actually does, somehow.

    • Muddybulldog@mylemmy.win
      link
      fedilink
      English
      arrow-up
      2
      ·
      1 year ago

      Paxlovid is a 3CL protease inhibitor. It modifies the primary enzyme that is common across all cornavirus.